Author:
Ezzalfani Monia,Dugué Audrey,Mollevi Caroline,Pulido Marina,Bonnetain Franck,Filleron Thomas,Gal Jocelyn,Gauthier Mélanie,Deley Marie Cécile Le,Le Tourneau Christophe,Médioni Jacques,Nguyen Jean-Michel,Chabaud Sylvie,Teixeira Luis,Thivat Emilie,You Benoît,Kramar Andrew,Paoletti Xavier
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Reference26 articles.
1. Dose escalation methods in phase I cancer clinical trials;Le Tourneau;J Natl Cancer Inst,2009
2. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors;Daud;Clin Cancer Res,2011
3. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer;Britten;Invest New Drugs,2014
4. Proposal for size justification of expanded cohort at phase-2-recommended dose;Penel;Invest New Drugs,2011
5. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials;Manji;J Clin Oncol,2013
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献